Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctors to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating infants with malignant brain or spinal cord tumors.

Condition or disease	Intervention/treatment	Phase
Brain Tumors; Central Nervous System Tumors; Neuroblastoma; Sarcoma	Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: conventional surgery; Procedure: peripheral blood stem cell transplantation	Phase 1

Detailed Description:

OBJECTIVES:

• Determine the maximum tolerated dose of thiotepa in infants with malignant brain or spinal cord tumors receiving intensive chemotherapy.
• Determine the feasibility and toxicity of intensive chemotherapy with peripheral blood stem cell (PBSC) rescue in these patients.
• Assess the feasibility of harvesting PBSCs in these patients.
• Determine the complete response rate and overall event-free survival rate in patients treated with this regimen.

OUTLINE: This is a pilot, multicenter study.

Patients undergo surgery for diagnosis and maximal tumor resection.

Within 6 weeks of surgery or when stable, patients begin induction chemotherapy comprising cisplatin IV over 6 hours on day 0; vincristine IV on days 0, 7, and 14; cyclophosphamide IV over 1 hour on days 1-2; and etoposide IV over 1 hour on days 0-2. Twenty four hours after the last cyclophosphamide dose, patients receive filgrastim (G-CSF) subcutaneously (SC) and undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Within 6 weeks after induction chemotherapy, patients receive consolidation chemotherapy comprising carboplatin IV over 2 hours on days 0-1 followed immediately by escalating doses of thiotepa IV over 2 hours. Patients then undergo peripheral blood stem cell transplantation 48 hours after the last thiotepa dose. Patients receive G-CSF SC daily on days 3 to 21. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Patients experiencing dose-limiting toxicity due to thiotepa are removed from the study.

Patients are followed at 4 weeks, every 3 months for 1 year, every 6 months for 3 years, and then annually for 3 years or until relapse.

PROJECTED ACCRUAL: A total of 83 patients will be accrued for this study within 1 year.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	94 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors
Study Start Date :	March 1998
Actual Primary Completion Date :	December 2007
Actual Study Completion Date :	October 2011

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm

Intervention/treatment

Experimental: Treatment (combination chemotherapy, PBSC transplant); Pts undergo conventional surgery for diagnosis & max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.

Biological: filgrastim; Given IV; Other Names: GRANULOCYTE COLONY-STIMULATING FACTOR; r-metHuG-CSF; G-CSF Drug: carboplatin; Given IV; Other Names: Paraplatin; CBDCA; NSC #241240 Drug: cisplatin; Given IV; Other Names: Cis-diamminedichloroplatinum II; Platinol-AQ; NSC #119875 Drug: cyclophosphamide; Given IV; Other Names: CTX; Cytoxan; NSC #026271 Drug: etoposide; Given IV; Other Names: VP-16; VePesid; Etopophos; NSC #141540 Drug: thiotepa; Given IV; Other Names: Tespa; Tspa; NSC #639 Drug: vincristine sulfate; Given IV; Other Names: VCR; Oncovin; NSC #067574 Procedure: conventional surgery Procedure: peripheral blood stem cell transplantation

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Feasibility [ Time Frame: Up to 4 weeks after completion of study treatment ]
   Demonstrate the feasibility of administering this regimen, to select an acceptable Thiotepa dose for Consolidation therapy, and to document significant toxicities and estimate their overall rates
2. Maximal tolerated dose of thiotepa for consolidation therapy [ Time Frame: 9 weeks ]
   The dose level will be assigned within 3 working days prior to beginning Consolidation.
3. Overall rates of significant toxicities including grade IV ototoxicity, electrolytic wasting (grade IV), and hemorrhagic cystitis (grade IV) [ Time Frame: Up to 6 years ]
   Estimates will be obtained using life-table methods with an event defined as the first occurrence of toxicity. Graded using the CCG Toxicity and Complications Criteria.

Secondary Outcome Measures :

1. Event Free Survival [ Time Frame: From the time of study entry to the first occurrence of death by any cause, progression or recurrence of disease or occurrence of a second malignant neoplasm, assessed up ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	up to 2 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven malignant brain or spinal cord tumor, including the following:

  • Primitive neuroectodermal tumor
  • Ganglioneuroblastoma
  • Medulloblastoma neuroblastoma
  • Desmoplastic medulloblastoma
  • Medulloepithelioma
  • Ependymoma neuroepithelioma
  • Anaplastic ependymoma germ cell tumor
  • Astrocytoma germinoma
  • Anaplastic astrocytoma
  • Embryonal carcinoma
  • Glioblastoma endodermal sinus tumor
  • Gliosarcoma malignant teratoma
  • Choroid plexus carcinoma
  • Mixed germ cell tumor
  • Cerebellar sarcoma
  • Pineoblastoma
  • Atypical teratoid/rhabdoid tumor
  • Choriocarcinoma
  • Teratoma (malignant or with malignant transformations)
• Diffusely involved brain stem tumors allowed if there is evidence of brain stem glioma by CT scan or MRI

PATIENT CHARACTERISTICS:

Age:

• 6 months to less than 3 years

Performance Status:

• Not specified

Life Expectancy:

• More than 8 weeks

Hematopoietic:

• Absolute neutrophil count greater than 1,000/mm^3
• Platelet count greater than 100,000/mm^3

Hepatic:

• Bilirubin less than 2.0 mg/dL

Renal:

• Glomerular filtration rate or creatinine clearance greater than 70 mL/min

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior biologic therapy

Chemotherapy:

• No prior chemotherapy

Endocrine therapy:

• Prior corticosteroids allowed

Radiotherapy:

• No prior radiotherapy

Surgery:

• No more than 6 weeks since prior surgery
• Recovered from prior surgery (stable)

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

  Show 71 Study Locations

Sponsors and Collaborators

Children's Oncology Group

National Cancer Institute (NCI)

Investigators

Study Chair:	Bruce H. Cohen, MD	The Cleveland Clinic

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Children's Oncology Group
ClinicalTrials.gov Identifier:	NCT00003141 History of Changes
Other Study ID Numbers:	99703; COG-99703 ( Other Identifier: Children's Oncology Group ); CCG-99703 ( Other Identifier: Children's Cancer Group ); CDR0000065924 ( Other Identifier: Clinical Trials.gov )
First Posted:	November 6, 2003
Last Update Posted:	March 28, 2014
Last Verified:	March 2014

Keywords provided by Children's Oncology Group:

childhood infratentorial ependymoma; childhood supratentorial ependymoma; disseminated neuroblastoma; stage 4S neuroblastoma; embryonal childhood rhabdomyosarcoma; childhood high-grade cerebral astrocytoma; childhood choroid plexus tumor; previously untreated childhood rhabdomyosarcoma; untreated childhood brain stem glioma; untreated childhood supratentorial primitive neuroectodermal tumor; untreated childhood cerebellar astrocytoma; untreated childhood medulloblastoma; newly diagnosed childhood ependymoma

localized resectable neuroblastoma; localized unresectable neuroblastoma; regional neuroblastoma; childhood spinal cord neoplasm; childhood atypical teratoid/rhabdoid tumor; childhood low-grade cerebral astrocytoma; childhood central nervous system choriocarcinoma; childhood central nervous system embryonal tumor; childhood central nervous system germinoma; childhood central nervous system mixed germ cell tumor; childhood central nervous system teratoma; childhood central nervous system yolk sac tumor

Additional relevant MeSH terms:

Neoplasms; Brain Neoplasms; Neuroblastoma; Nervous System Neoplasms; Central Nervous System Neoplasms; Neoplasms by Site; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuroectodermal Tumors, Primitive, Peripheral; Neuroectodermal Tumors, Primitive; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type	Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Etoposide phosphate; Cisplatin; Cyclophosphamide; Carboplatin; Etoposide; Vincristine; Thiotepa; Lenograstim; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents